


=>

Uploading C:\Program Files\Stnexp\Queries\10562122-third.str



chain nodes :

11 12 13 14 21 22 23 24 25 31 32 39 40 41 42 43

ring nodes :

1 2 3 4 5 6 7 8 9 15 16 17 18 19 20 26 27 28 29 30 33 34 35  
36 37 38

chain bonds :

7-12 9-11 12-13 12-14 14-15 17-22 18-23 20-21 23-24 24-25 24-26 28-42  
30-31 31-32 32-33 36-39 39-40 39-41 42-43

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-9 15-16 15-20 16-17 17-18 18-19  
19-20 26-27 26-30 27-28 28-29 29-30 33-34 33-38 34-35 35-36 36-37 37-38

exact/norm bonds :

5-6 5-7 6-9 7-8 7-12 8-9 9-11 12-13 12-14 14-15 17-22 18-23 20-21 23-24  
24-25 24-26 26-27 26-30 27-28 28-29 28-42 29-30 30-31 31-32 32-33 33-34  
33-38 34-35  
35-36 36-37 36-39 37-38 39-40 39-41 42-43

normalized bonds :

1-2 1-6 2-3 3-4 4-5 15-16 15-20 16-17 17-18 18-19 19-20

isolated ring systems :

containing 1 : 15 : 26 : 33 :


Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 11:CLASS  
12:CLASS 13:CLASS 14:CLASS 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom 20:Atom  
21:CLASS 22:CLASS  
23:CLASS 24:CLASS 25:CLASS 26:Atom 27:Atom 28:Atom 29:Atom 30:Atom 31:CLASS  
32:CLASS  
33:Atom 34:Atom 35:Atom 36:Atom 37:Atom 38:Atom 39:CLASS 40:CLASS 41:CLASS  
42:CLASS 43:CLASS

L1 STRUCTURE UPLOADED

=>

Uploading C:\Program Files\Stnexp\Queries\10562122-not.str



```

chain nodes :
11 12 13 14 21 22 23 24 25 31 32 39 40 41 42 43 44
ring nodes :
1 2 3 4 5 6 7 8 9 15 16 17 18 19 20 26 27 28 29 30 33 34 35
36 37 38
chain bonds :
7-12 9-11 12-13 12-14 14-15 17-22 18-23 20-21 23-24 24-25 24-26 28-42
30-31 31-32 32-33 36-39 39-40 39-41 41-44 42-43
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-9 15-16 15-20 16-17 17-18 18-19
19-20 26-27 26-30 27-28 28-29 29-30 33-34 33-38 34-35 35-36 36-37 37-38
exact/norm bonds :
5-6 5-7 6-9 7-8 7-12 8-9 9-11 12-13 12-14 14-15 17-22 18-23 20-21 23-24
24-25 24-26 26-27 26-30 27-28 28-29 28-42 29-30 30-31 31-32 32-33 33-34
33-38 34-35
35-36 36-37 36-39 37-38 39-40 39-41 41-44 42-43
normalized bonds :
1-2 1-6 2-3 3-4 4-5 15-16 15-20 16-17 17-18 18-19 19-20
isolated ring systems :
containing 1 : 15 : 26 : 33 :
```

```

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 11:CLASS
12:CLASS 13:CLASS 14:CLASS 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom 20:Atom
21:CLASS 22:CLASS
23:CLASS 24:CLASS 25:CLASS 26:Atom 27:Atom 28:Atom 29:Atom 30:Atom 31:CLASS
32:CLASS
33:Atom 34:Atom 35:Atom 36:Atom 37:Atom 38:Atom 39:CLASS 40:CLASS 41:CLASS
42:CLASS 43:CLASS
44:CLASS
```

L3 STRUCTURE UPLOADED

=> d his

(FILE 'HOME' ENTERED AT 07:24:11 ON 18 APR 2008)

FILE 'REGISTRY' ENTERED AT 07:24:17 ON 18 APR 2008

L1 STRUCTURE UPLOADED

L2 7 S L1 SSS FULL

FILE 'STNGUIDE' ENTERED AT 07:25:03 ON 18 APR 2008

FILE 'REGISTRY' ENTERED AT 07:25:48 ON 18 APR 2008

L3 STRUCTURE UPLOADED  
L4 4 S L3 SSS FULL SUB=L2  
L5 3 S L2 NOT L4


FILE 'CAPLUS' ENTERED AT 07:26:42 ON 18 APR 2008

L6 5 S L5  
L7 1 S US200!-562122/APPS  
L8 1 S L6 AND L7  
L9 4 S L6 NOT L7

=> d 18 bib abs

L8 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2008 ACS on STN  
AN 2005:99497 CAPLUS <<LOGINID::20080418>>  
DN 142:197874  
TI Preparation of indole derivative containing cyclohexanecarboxylic acid moiety as VLA-4 inhibitors  
IN Ono, Makoto; Noguchi, Shigeru  
PA Daiichi Pharmaceutical Co., Ltd., Japan  
SO PCT Int. Appl., 19 pp.  
CODEN: PIXXD2  
DT Patent  
LA Japanese  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	---	-----	-----	-----
PI	WO 2005009992	A1	20050203	WO 2004-JP10457	20040723
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2528586	A1	20050203	CA 2004-2528586	20040723
	EP 1650205	A1	20060426	EP 2004-747846	20040723
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
	CN 1826336	A	20060830	CN 2004-80021230	20040723
	US 20070105936	A1	20070510	US 2005-562122	20051223 <--
	MX 2006PA00850	A	20060330	MX 2006-PA850	20060123
PRAI	JP 2003-201062	A	20030724		
	WO 2004-JP10457	W	20040723		
OS	CASREACT 142:197874				
GI					




AB A VLA-4 (very late antigen-4) inhibitory compound I sodium salt pentahydrate having high solubility in water and long-term stability was prepared Thus, EDCI-mediated acylation of trans-4-[(4S)-methoxy-(2S)-pyrrolidinylmethoxy]cyclohexanecarboxylic acid Me ester with [2,5-dichloro-4-[(1-methyl-1H-3-indolylcarbonyl)amino]phenyl]acetic acid, followed by treatment with aqueous NaOH afforded compound I sodium salt pentahydrate. Compound I sodium salt pentahydrate is claimed useful for the treatment of inflammation, diabetes, etc.

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d 19 tot bib abs hitstr

L9 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2008 ACS on STN  
AN 2007:352105 CAPLUS <<LOGINID::20080418>>  
DN 146:379822  
TI Stereoselective preparation of trans-cyclohexanes as intermediates for VLA-4 inhibitors  
IN Chiba, Atsushi  
PA Daiichi Seiyaku Co., Ltd., Japan  
SO Jpn. Kokai Tokkyo Koho, 61pp.  
CODEN: JKXXAF  
DT Patent  
LA Japanese  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 2007077032	A	20070329	JP 2005-263466	20050912
PRAI	JP 2005-263466		20050912		
OS	MARPAT 146:379822				
GI					



AB Title compds. I [Z1 =  $\beta$ -OR6; Z2 = H; R1a, R1b = lower alkyl,

(un)substituted Ph, (un)substituted PhCH<sub>2</sub>; R<sub>6</sub> = lower alkyl] are prepared by esterification of trans-4-HOZ<sub>3</sub>CO<sub>2</sub>CMeR<sub>1a</sub>R<sub>1b</sub> (Z<sub>3</sub> = cyclohexanediyl; R<sub>1a</sub>, R<sub>1b</sub> = same as above) with (S)-(+)-epihalohydrin, treatment with H<sub>2</sub>C:CHX<sub>3</sub> (X<sub>3</sub> = MgCl, MgBr, MgI, Li), Mitsunobu reaction with [(un)substituted benzo]succinimide, treatment with hydrazines, amidation with (un)substituted benzoyl compds., cyclization in the presence of iodine, and via I [Z<sub>1</sub> = α-R<sub>3</sub>CO<sub>2</sub>; Z<sub>2</sub> = H; R<sub>1a</sub>, R<sub>1b</sub> = same as above; R<sub>3</sub> = (un)substituted Ph], I [Z<sub>2</sub> = R<sub>4</sub>O<sub>2</sub>C; R<sub>4</sub> = (un)substituted PhCH<sub>2</sub>, Ph<sub>2</sub>CH; Z<sub>1</sub>, R<sub>3</sub>, R<sub>1a</sub>, R<sub>1b</sub> = same as above], I [Z<sub>1</sub> = α-OH; Z<sub>2</sub>, R<sub>4</sub>, R<sub>1a</sub>, R<sub>1b</sub> = same as above], I [Z<sub>1</sub> = β-R<sub>5</sub>CO<sub>2</sub>; R<sub>5</sub> = H, lower alkyl, (un)substituted Ph; Z<sub>2</sub>, R<sub>4</sub>, R<sub>1a</sub>, R<sub>1b</sub> = same as above], and I [Z<sub>1</sub> = β-OH; Z<sub>2</sub>, R<sub>4</sub>, R<sub>1a</sub>, R<sub>1b</sub> = same as above]. Thus, I (Z<sub>1</sub> = α-OH, Z<sub>2</sub> = cbz, R<sub>1a</sub>, R<sub>1b</sub> = Me) was formylated, hydrolyzed, treated with MeI, and deprotected to give I (Z<sub>1</sub> = β-MeO, Z<sub>2</sub> = H, R<sub>1a</sub>, R<sub>1b</sub> = same as above), which was amidated with 2,5-dichloro-4-[(1-methylindol-3-yl)carboxamido]phenylacetic acid to afford the corresponding amide.


IT 793669-59-7P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(stereoselective preparation of VLA-4 inhibitors from trans-cyclohexanecarboxylic acid tertiary alc. esters)

RN 793669-59-7 CAPLUS

CN Cyclohexanecarboxylic acid, 4-[[[(2S,4S)-1-[2-[2,5-dichloro-4-[(1-methyl-1H-indol-3-yl)carbonyl]amino]phenyl]acetyl]-4-methoxy-2-pyrrolidinyl]methoxy]-, trans- (CA INDEX NAME)

Absolute stereochemistry.



L9 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2005:638842 CAPLUS <<LOGINID::20080418>>

DN 143:153280

TI Process for preparation of pyrrolidine derivatives

IN Takayanagi, Yoshihiro; Yamada, Toshihide; Furuya, Yukito; Yoneda, Yoshiyuki

PA Daiichi Pharmaceutical Co., Ltd., Japan

SO PCT Int. Appl., 76 pp.

CODEN: PIXXD2

DT Patent

LA Japanese

FAN.CNT 1

PATENT NO.


KIND

DATE

APPLICATION NO.

DATE

PI	WO 2005066124	A1	20050721	WO 2004-JP19581	20041227
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	BW, BH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	EP 1698621	A1	20060906	EP 2004-807936	20041227
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS			
	US 20070149607	A1	20070628	US 2006-584141	20060626
PRAI	JP 2003-431686	A	20031226		
	WO 2004-JP19581	W	20041227		
OS	MARPAT 143:153280				
GI					




AB Disclosed is an advantageous method for producing an intermediate compound I [wherein X = H or halo; Y = halo or alkoxy; R2 = alkyl; R4 = (un)substituted alkyl or aralkyl], which is useful for obtaining a safe compound having excellent VLA-4 inhibitory activity. For example, the compound I•Na (X = Y = Cl; R2 = Me; R4 = H) was prepared in a multi-step synthesis.

IT 858362-36-4P  
 RL: IMF (Industrial manufacture); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent) (intermediate; preparation of pyrrolidine derivs.)

RN 858362-36-4 CAPLUS

CN Cyclohexanecarboxylic acid, 4-[[[(2S,4S)-1-[2-[2,5-dichloro-4-[[[(1-methyl-1H-indol-3-yl)carbonyl]amino]phenyl]acetyl]-4-methoxy-2-pyrrolidinyl]methoxy]-, sodium salt (1:1), trans- (CA INDEX NAME)

Absolute stereochemistry.




● Na

IT 835901-02-5P  
 RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)  
 (preparation of pyrrolidine derivs.)  
 RN 835901-02-5 CAPLUS  
 CN Cyclohexanecarboxylic acid, 4-[[[(2S,4S)-1-[[2,5-dichloro-4-[[[(1-methyl-1H-indol-3-yl)carbonyl]amino]phenyl]acetyl]-4-methoxy-2-pyrrolidinyl]methoxy]-, monosodium salt, pentahydrate, trans- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




● Na

● 5 H<sub>2</sub>O

RE.CNT 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2008 ACS on STN  
AN 2005:612230 CAPLUS <<LOGINID::20080418>>  
DN 143:133271  
TI Process for preparation of phenylacetic acid derivatives  
IN Nakayama, Atsushi; Noguchi, Shigeru; Furuya, Yukito; Okano, Katsuhiko  
PA Daiichi Pharmaceutical Co., Ltd, Japan  
SO PCT Int. Appl., 68 pp.  
CODEN: PIXXD2  
DT Patent  
LA Japanese  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005063678	A1	20050714	WO 2004-JP19578	20041227
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	EP 1698611	A1	20060906	EP 2004-807933	20041227
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS			
	US 20070149606	A1	20070628	US 2006-584240	20060626
PRAI	JP 2003-431680	A	20031226		
	JP 2004-283082	A	20040929		
	JP 2004-312335	A	20041027		
	WO 2004-JP19578	W	20041227		
OS	MARPAT 143:133271				
GI					





AB This invention pertains to a method for producing heterocycle substituted phenylacetic acid derivs. I [wherein R1 = (un)substituted aryl or heteroaryl; R2 = (un)substituted alkoxy, aralkyloxy, phenoxy, etc.; X = H or halo; Y = halo or alkoxy]. For example, the compound II was prepared in a multi-step synthesis. This invention provides a convenient method to prepare phenylacetic acid derivs. which are useful intermediates for the preparation of medicinal compds.


IT 858362-36-4P

RL: IMF (Industrial manufacture); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent) (intermediate; preparation of phenylacetic acid derivs.)

RN 858362-36-4 CAPLUS

CN Cyclohexanecarboxylic acid, 4-[[[(2S,4S)-1-[2-[2,5-dichloro-4-[[[(1-methyl-1H-indol-3-yl)carbonyl]amino]phenyl]acetyl]-4-methoxy-2-pyrrolidinyl]methoxy]-, sodium salt (1:1), trans- (CA INDEX NAME)

Absolute stereochemistry.




IT 835901-02-5P

RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation) (preparation of phenylacetic acid derivs.)

RN 835901-02-5 CAPLUS

CN Cyclohexanecarboxylic acid, 4-[[[(2S,4S)-1-[2-[2,5-dichloro-4-[[[(1-methyl-1H-indol-3-yl)carbonyl]amino]phenyl]acetyl]-4-methoxy-2-pyrrolidinyl]methoxy]-, monosodium salt, pentahydrate, trans- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● Na


● 5 H<sub>2</sub>O

RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2008 ACS on STN  
AN 2004:996121 CAPLUS <<LOGINID::20080418>>  
DN 141:410814  
TI Process for preparation of pyrrolidine derivatives  
IN Nakayama, Atsushi; Machinaga, Nobuo; Yoneda, Yoshiyuki; Setoguchi, Masaki  
PA Daiichi Pharmaceutical Co., Ltd., Japan  
SO PCT Int. Appl., 58 pp.  
CODEN: PIXXD2  
DT Patent  
LA Japanese  
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004099136	A1	20041118	WO 2004-JP6471	20040507
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,				

SN, TD, TG  
 EP 1623975 A1 20060208 EP 2004-731729 20040507  
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
 IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK  
 US 20070105935 A1 20070510 US 2005-556043 20051108  
 US 7345179 B2 20080318  
 PRAI JP 2003-131978 A 20030509  
 JP 2003-144430 A 20030522  
 JP 2003-209579 A 20030829  
 WO 2004-JP6471 W 20040507  
 OS MARPAT 141:410814  
 GI




AB This invention pertains to a method for industrially advantageously producing 1,4-trans-cyclohexanecarboxylic acid derivative I which comprises reduction and isomerization processes. Trans-4-[(4S)-Methoxy-(2S)-pyrrolidinylmethoxy]cyclohexanecarboxylic acid Et ester (preparation given) was reacted with 2,5-dichloro-4-[(1-methyl-1H-indol-3-yl)carboxamido]phenylacetic acid (preparation given) to give I Et ester (99.8%).

IT 793669-59-7P  
 RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)  
 (preparation of pyrrolidine derivs.)

RN 793669-59-7 CAPLUS

CN Cyclohexanecarboxylic acid, 4-[[[(2S,4S)-1-[2-[2,5-dichloro-4-[(1-methyl-1H-indol-3-yl)carbonyl]amino]phenyl]acetyl]-4-methoxy-2-pyrrolidinyl]methoxy]-, trans- (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT